PLK1 inhibitors for the treatment of colorectal cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Polo-like kinase 1 (PLK1) is a critical regulator of cell division (mitosis).
• PLK1 is a promising target for anti-cancer drug development.
• Existing PLK1 inhibitors have faced challenges with clinical approval due to low response rates.

Purpose of the Study:

• To review preclinical and clinical data on PLK1 inhibitors in cancer treatment.
• To focus on the efficacy of PLK1 inhibitors specifically in colorectal cancer.
• To identify potential for PLK1 inhibitors in treating KRAS-mutated colorectal cancer.

Main Methods:

• Review of published preclinical studies on PLK1 inhibitors.
• Analysis of data from clinical trials involving PLK1 inhibitors.
• Focus on studies related to colorectal cancer, particularly with KRAS mutations.

Main Results:

• A recent Phase I trial showed a 44% partial response rate for onvansertib in KRAS-mutated metastatic colorectal cancer.
• Preclinical data suggest PLK1 inhibition can impact colorectal cancer cell proliferation.
• Despite promise, no PLK1 inhibitors are currently approved for clinical use.

Conclusions:

• PLK1 inhibitors, like onvansertib, demonstrate potential therapeutic value in KRAS-mutated colorectal cancer.
• Further clinical investigation is warranted to overcome limitations and achieve regulatory approval.
• This review aims to guide future research in PLK1-targeted colorectal cancer therapy.